Literature Review on Evolving Dyslipidemia AHA and ACC Guidelines 2001 till 2026
Journal of Medical Science and Clinical Research · 13.07.2026 · 14 (07) · 25-34
DOI: 10.18535/jmscr/v14i07.05 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Medical Science and Clinical Research, online erschienen am 13.07.2026. Verfasst von Dr Teeba Salwan Kamal Abbood und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Executive Summary The modern US approach to dyslipidemia management has now evolved through four linked phases rather than only three distinct eras. The first was the ATP III era, built around explicit LDL-C treatment goals, Framingham-based risk stratification, and escalation of drug therapy until a numerical cholesterol target was reached. ATP III's 2004 update tightened this strategy by introducing an optional LDL-C goal below 70 mg/dL for very high-risk patients after influential statin trials such as HPS and PROVE-IT.[1] The second era began with the 2013 ACC/AHA cholesterol guideline, which made the most disruptive conceptual shift in the field. It abandoned routine treat-to-target LDL-C titration, prioritized four statin benefit groups, and based treatment intensity on randomized-trial evidence rather than on achieving specific LDL-C targets. The Pooled Cohort Equations became the principal tool for estimating 10-year ASCVD risk in primary prevention, although they were developed for nonHispanic White and Black adults and were soon criticized for calibration issues in some external cohorts.[2] The third era, beginning in 2018 and extended through the 2022/2023 documents, did not simply reverse the 2013 strategy, instead, it created a hybrid model: statin intensity remained the foundation, but LDL-C thresholds re-emerged to guide add-on therapy. The 2018 multisociety guideline introduced risk enhancers and coronary artery calcium scoring to refine primary prevention decisions, while the 2022 ACC non-statin pathway and 2023 chronic coronary disease guideline operationalised when to add ezetimibe, PCSK9 inhibitors, icosapent ethyl, bempedoic acid, and inclisiran. In practice, the field therefore moved from treat-to-LDL goal, to treat-bystatin intensity, to a threshold-based combination approach that was closer to goal-directed care than the 2013 document but still anchored in trial-proven statin therapy.[3]
Zitieren
APA
Abbood, D. T. S. K., & Rabeei, D. Y. A. (2026). Literature Review on Evolving Dyslipidemia AHA and ACC Guidelines 2001 till 2026. Journal of Medical Science and Clinical Research, 14(07), 25-34. https://doi.org/10.18535/jmscr/v14i07.05
Vancouver
Abbood DTSK, Rabeei DYA. Literature Review on Evolving Dyslipidemia AHA and ACC Guidelines 2001 till 2026. Journal of Medical Science and Clinical Research. 2026;14(07):25-34. doi:10.18535/jmscr/v14i07.05
BibTeX
@article{Abbood2026,
author = {Abbood, Dr Teeba Salwan Kamal and Rabeei, Dr Yosaf Al},
title = {Literature Review on Evolving Dyslipidemia AHA and ACC Guidelines 2001 till 2026},
journal = {Journal of Medical Science and Clinical Research},
year = {2026},
volume = {14},
number = {07},
pages = {25--34},
doi = {10.18535/jmscr/v14i07.05}
}
EUVIMED